Although the ER-α antagonist ICI 182,780 has been widely used to treat breast cancer in postmenopausal women (Nathan & Schmid, 2017), it is described that this substance can also activate GPER (Filardo et al, 2000; Meyer et al, 2010). This evidence concerns the gene ESR1 and breast cancer.